Many women are confused about the meaning of the phrase “triple negative breast cancer not.” However, if you are one of those women, this article will answer some of your questions. It will explain why your doctor may not diagnose you with triple negative breast cancer. You may be wondering what this term actually means and how it will affect your treatment options. To find out, read on to learn more about this disease and its genetic makeup. There are several subtypes, so knowing what they are can help you make an informed decision.
This type of breast cancer is caused by a mutation in the BRCA1 gene. It is more likely to occur in young African-American women. This mutation increases the chances of developing triple-negative breast cancer. Because of these differences, the treatment options for this disease are very different than those of other types of breast cancer. And if you are diagnosed with this type of breast cancer, you will have to undergo special tests and have it confirmed through biopsy.
Three other types of triple-negative breast cancer can be classified as apocrine or metaplastic. The former has a central acellular zone with prominent tumor infiltrating lymphocytes. Forty-three cases (87%) were classified as invasive ductal carcinomas without special morphologic features according to WHO classification criteria. In addition to this, six cases (15%) had a large central acellular zone and prominent tumor infiltrating lymphocytes, but without any overlap with the above two categories. Moreover, twenty-two cases had no specific morphologic features.
The scientific community is gaining more knowledge about the phenotype of triple-negative breast cancer. It is a heterogeneous subtype of breast cancer that lacks the hormone receptors estrogen and progesterone and lacks overexpression of HER2 protein. Because of these differences, triple-negative tumors are categorized as “basal-like” and don’t respond to hormone-based therapies. Fortunately, there are a variety of treatments that are specific to this subtype.
While you may think you have triple-negative breast cancer, your doctor might not be able to do that. While it may be difficult to get a diagnosis, it’s important to keep these results and re-analyze them in order to find out if your disease is indeed triple-negative. While you’re waiting to learn more, you can watch a free webinar to find out how you can best prepare for this difficult time.
In addition to surgery, chemotherapy is also available. While hormone treatments won’t help with triple-negative breast cancer, chemotherapy and immunotherapy can often be used with surgery. Chemotherapy and hormone treatments won’t work if the cancer has spread to your lymph nodes or skin. Your doctor may also recommend hormonal treatments or immunotherapy. Sometimes, chemotherapy isn’t an option, but it may be a good option in certain cases.
Anti-angiogenic therapies can work in patients with triple-negative breast cancer. One study compares the PARP inhibitor veliparib with carboplatin. Moreover, a randomized phase 3 study conducted in New Zealand compares carboplatin alone with carboplatin and bevacizumab. Both drugs were found to be equally effective in treating triple-negative breast cancer. Those who had a BRCA1 mutation in their tumors also responded well to paclitaxel, the chemotherapy for triple-negative breast cancer.
